Sustained and targeted delivery of checkpoint inhibitors by metal-organic frameworks for cancer immunotherapy.
Shahad K AlsaiariSomayah S QutubShichao SunWalaa BaslymanMansour AldehaimanMram AlyamiAbdulaziz M AlmalikRabih HalwaniJasmeen S MerzabanZheng-Wei MaoPublished in: Science advances (2021)
The major impediments to the implementation of cancer immunotherapies are the sustained immune effect and the targeted delivery of these therapeutics, as they have life-threatening adverse effects. In this work, biomimetic metal-organic frameworks [zeolitic imidazolate frameworks (ZIFs)] are used for the controlled delivery of nivolumab (NV), a monoclonal antibody checkpoint inhibitor that was U.S. Food and Drug Administration-approved back in 2014. The sustained release behavior of NV-ZIF has shown a higher efficacy than the naked NV to activate T cells in hematological malignancies. The system was further modified by coating NV-ZIF with cancer cell membrane to enable tumor-specific targeted delivery while treating solid tumors. We envisage that such a biocompatible and biodegradable immunotherapeutic delivery system may promote the development and the translation of hybrid superstructures into smart and personalized delivery platforms.